Compare VC & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VC | LQDA |
|---|---|---|
| Founded | 2000 | 2004 |
| Country | United States | United States |
| Employees | 10000 | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 3.1B |
| IPO Year | 2000 | 2020 |
| Metric | VC | LQDA |
|---|---|---|
| Price | $87.55 | $36.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 11 |
| Target Price | ★ $120.83 | $41.00 |
| AVG Volume (30 Days) | 476.7K | ★ 1.4M |
| Earning Date | 04-23-2026 | 03-05-2026 |
| Dividend Yield | ★ 1.71% | N/A |
| EPS Growth | N/A | ★ 51.81 |
| EPS | ★ 7.28 | N/A |
| Revenue | ★ $3,768,000,000.00 | $158,320,000.00 |
| Revenue This Year | $2.31 | $265.61 |
| Revenue Next Year | $5.24 | $62.82 |
| P/E Ratio | $12.04 | ★ N/A |
| Revenue Growth | N/A | ★ 1031.18 |
| 52 Week Low | $65.17 | $11.26 |
| 52 Week High | $128.32 | $46.67 |
| Indicator | VC | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 40.49 | 52.48 |
| Support Level | $82.35 | $31.75 |
| Resistance Level | $105.72 | $39.19 |
| Average True Range (ATR) | 2.57 | 1.83 |
| MACD | 0.01 | 0.15 |
| Stochastic Oscillator | 42.09 | 51.61 |
Visteon Corp is an automotive supplier. It manufactures electronics products for original equipment vehicle manufacturers including Ford, Nissan, Renault, Mazda, BMW, General Motors, and Honda, etc. The company offers information displays, instrument clusters, head-up displays, infotainment systems, telematics solutions, and Smartcore. The Company's reportable segment is Electronics. The Electronics segment provides vehicle cockpit electronics products to customers, including digital instrument clusters, domain controllers with integrated driver assistance systems, displays, Android-based infotainment systems, and battery management systems. Geographically, it operates in North America, Europe, China, Asia-Pacific, and South America and Others.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.